CME Group is a stock—the world's largest derivatives marketplace operator, running the Chicago Mercantile Exchange, CBOT, NYMEX, and COMEX. Because targets vary widely, the $330 figure is the average of the six verified targets that exceed the current price, not a published Street consensus. The overall mean of all 11 targets reviewed is about $300, and the full range spans $230 (Bank of America Securities, Underperform) to $367 (J.P. Morgan, which upgraded the stock to Buy in late October 2026).
The dispersion is striking. On the bullish side, Morgan Stanley lifted its target to $359 and Piper Sandler to $330, citing new products and a structural growth runway. UBS moved to $310 while keeping a Hold, and Raymond James held an Outperform view near $320. On the cautious side, Goldman Sachs raised its target to $271 but retained a Sell, Deutsche Bank downgraded to Hold on valuation in August, and Barclays sits at $270. The gap between the highest and lowest targets reflects genuine disagreement over how much of CME's recent volume-driven growth is durable versus tied to temporary market volatility.
With the stock near $293 and the target at $330, the required move is roughly 12%—a substantial advance rather than a modest drift. Notably, CME's 52-week range is $218.31 to $329.16, so the $330 objective sits essentially at the stock's prior high.
The fundamental backdrop is strong. Third-quarter 2026 revenue rose 13% to a record $1.74 billion, adjusted diluted EPS (earnings per share) climbed 13% to $3.02, and average daily volume (ADV) reached a third-quarter record of 29.4 million contracts, up 16%, with double-digit growth across all six asset classes. Market data revenue hit a record $243 million, its 34th consecutive quarter of growth. The path toward $330 would likely require continued volume momentum and successful adoption of initiatives such as the December 2026 CME Securities Clearing launch tied to the U.S. Treasury clearing mandate.
Several factors could help the stock retake and exceed its prior high. Broad-based volume growth, particularly a 23% rise in equity-complex trading and 22% international ADV growth, supports clearing and transaction fees. The market-data franchise provides recurring, high-margin revenue. New products—single-stock futures, 24/7 gold and silver trading, and E-nano equity index futures—offer incremental volume opportunities. Management also reported a record of roughly $100 billion in average daily capital efficiencies, which strengthens client stickiness. Finally, nearly $1 billion returned to shareholders in the quarter through dividends and buybacks underscores strong cash generation.
Valuation is the central concern. The stock trades near 24 times trailing earnings after a sharp rally, leaving little room for error, and Deutsche Bank's valuation-driven downgrade reflects this. Competition is rising, with Bank of America flagging Intercontinental Exchange (ICE) in energy and BGC Group (BGC) in rates as threats to market share. Because so much recent growth is tied to market uncertainty, a period of calmer markets could slow volume growth. Higher equity volumes also raise license-fee costs, which could cap margin expansion, and a high dividend payout ratio has drawn questions about dividend sustainability.
The $330 target is also a meaningful technical level: it sits just above the 52-week high of $329.16 set in March 2026, which now acts as the key resistance zone. A sustained move through that area would represent a breakout to new highs. On the downside, the stock's recent action near the $278–$279 zone (around its 50-day moving average) is a nearby support level, with the 52-week low of $218.31 representing the deeper structural floor. The long-term trend remains upward, but the stock is currently consolidating below its prior peak.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts apply different time frames. Investors should watch the December 2026 CME Securities Clearing launch and subsequent adoption, monthly volume and open-interest reports, and fourth-quarter earnings, where consensus points to sequentially lower EPS. Ongoing analyst revisions—several firms moved targets immediately after the October earnings report—and the cloud migration to Google Cloud are also worth tracking, along with interest-rate and volatility conditions that drive trading activity.
For traders seeking a more systematic view of shifting conditions, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This can help investors discover new opportunities, monitor existing positions, and spot emerging trends more efficiently than manual review alone. Consider exploring these signals as a complement to traditional research.
The question of whether CME can reach $330 is really a question about whether its record volume and data growth can overcome valuation skepticism. The target—an average of the six above-price analyst targets—implies a roughly 12% advance that would take the stock back to its 52-week high. Record volumes, a durable data franchise, and new product initiatives provide genuine support, while rich valuation, competitive pressure, and volatility dependence are the principal obstacles. The wide $230-to-$367 analyst range underscores that this is far from a settled debate, and investors should monitor volume trends, the securities clearing launch, and upcoming earnings before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CME has been loosely correlated with ICE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CME jumps, then ICE could also see price increases.
| Ticker / NAME | Correlation To CME | 1D Price Change % | ||
|---|---|---|---|---|
| CME | 100% | -0.42% | ||
| ICE - CME | 51% Loosely correlated | -0.24% | ||
| TW - CME | 45% Loosely correlated | -1.42% | ||
| NDAQ - CME | 37% Loosely correlated | +0.57% | ||
| MKTX - CME | 35% Loosely correlated | +0.06% | ||
| MSCI - CME | 31% Poorly correlated | +0.05% | ||
More | ||||
| Ticker / NAME | Correlation To CME | 1D Price Change % |
|---|---|---|
| CME | 100% | -0.42% |
| Financial Publishing/Services industry (14 stocks) | 17% Poorly correlated | -1.32% |
| Commercial Services industry (91 stocks) | 3% Poorly correlated | -0.94% |